A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s diseaseStephen Salloway, Paul Aisen, Jason Hassenstab et al.|Nature Medicine|2021Cited by 365
Disease staging of Alzheimer’s disease using a CSF-based biomarker modelGemma Salvadó, Oskar Hansson, Kanta Horie et al.|Nature Aging|2024Cited by 108
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker testsNoëlle Warmenhoven, Oskar Hansson, Gemma Salvadó et al.|Brain|2024Cited by 95
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J. Bateman, Bruno Dubois, Yan Li et al.|The Lancet Neurology|2025Cited by 39
P2‐076: A NOVEL ALTERNATIVE MODEL TO MMRM AS THE PRIMARY MODEL FOR SPORADIC AD CLINICAL TRIALS: THE PROPORTIONAL MMRMGuoqiao Wang, Randall J. Bateman, Chengjie Xiong et al.|Alzheimer s & Dementia|2018Cited by 2